Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-10-24
2011-11-29
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C424S130100, C424S133100, C424S134100
Reexamination Certificate
active
08067549
ABSTRACT:
The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
REFERENCES:
patent: 4150949 (1979-04-01), Smith
patent: 4816450 (1989-03-01), Bell et al.
patent: 4937232 (1990-06-01), Bell et al.
patent: 5079263 (1992-01-01), Zeeck et al.
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5248824 (1993-09-01), Igarashi et al.
patent: 5260288 (1993-11-01), Igarashi et al.
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5369030 (1994-11-01), Hannun et al.
patent: 5391800 (1995-02-01), Igarashi et al.
patent: 5430160 (1995-07-01), Boumendjel et al.
patent: 5444087 (1995-08-01), Patel et al.
patent: 5585476 (1996-12-01), MacLennan et al.
patent: 5627171 (1997-05-01), Park et al.
patent: 5663404 (1997-09-01), Igarashi et al.
patent: 5677288 (1997-10-01), Marangos
patent: 5677337 (1997-10-01), Wei et al.
patent: 5851782 (1998-12-01), Hannun et al.
patent: 5877167 (1999-03-01), Igarashi et al.
patent: 5919687 (1999-07-01), Chatterjee
patent: 5929039 (1999-07-01), Woodcock et al.
patent: 5989803 (1999-11-01), Tabas et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6057126 (2000-05-01), Munroe et al.
patent: 6130067 (2000-10-01), Tsui
patent: 6140060 (2000-10-01), Chun et al.
patent: 6187562 (2001-02-01), Duckworth et al.
patent: 6210976 (2001-04-01), Sabbadini
patent: 6284798 (2001-09-01), Amtmann et al.
patent: 6306911 (2001-10-01), Wachter et al.
patent: 6323201 (2001-11-01), Carson et al.
patent: 6352844 (2002-03-01), Maurer et al.
patent: 6423527 (2002-07-01), Saba et al.
patent: 6534322 (2003-03-01), Sabbadini
patent: 6534323 (2003-03-01), Sabbadini
patent: 6610835 (2003-08-01), Liotta et al.
patent: 6613322 (2003-09-01), Tabas et al.
patent: 6649362 (2003-11-01), Gamble et al.
patent: 6858383 (2005-02-01), Sabbadini
patent: 6881546 (2005-04-01), Sabbadini
patent: 7169390 (2007-01-01), Sabbadini
patent: 2001/0041688 (2001-11-01), Waeber et al.
patent: 2002/0150582 (2002-10-01), Friedrichs et al.
patent: 2003/0125533 (2003-07-01), Kossida et al.
patent: 2003/0219782 (2003-11-01), Saba et al.
patent: 2008/0213274 (2008-09-01), Sabbadini et al.
patent: 0173648 (1986-03-01), None
patent: 0173663 (1986-03-01), None
patent: 09-110722 (1987-04-01), None
patent: 2000-293181 (2000-10-01), None
patent: WO 97/44019 (1997-11-01), None
patent: WO 98/03529 (1998-01-01), None
patent: WO 98/28445 (1998-07-01), None
patent: WO 98/40349 (1998-09-01), None
patent: WO 98/57179 (1998-12-01), None
patent: WO 99/07855 (1999-02-01), None
patent: WO 99/12890 (1999-03-01), None
patent: WO 99/16888 (1999-04-01), None
patent: WO 99/33972 (1999-07-01), None
patent: WO 99/38983 (1999-08-01), None
patent: WO 99/41265 (1999-08-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 99/46277 (1999-09-01), None
patent: WO 99/61581 (1999-12-01), None
patent: WO 00/00593 (2000-01-01), None
patent: WO 00/21919 (2000-04-01), None
patent: WO 00/40262 (2000-07-01), None
patent: WO 00/52173 (2000-09-01), None
patent: WO 00/56135 (2000-09-01), None
patent: WO 00/58448 (2000-10-01), None
patent: WO 00/58491 (2000-10-01), None
patent: WO 00/59517 (2000-10-01), None
patent: WO 00/70028 (2000-11-01), None
patent: WO 00/72833 (2000-12-01), None
patent: WO 01/04108 (2001-01-01), None
patent: WO 01/04139 (2001-01-01), None
patent: WO 01/07418 (2001-02-01), None
patent: WO 01/31029 (2001-05-01), None
patent: WO 01/38295 (2001-05-01), None
patent: WO 01/55410 (2001-08-01), None
patent: WO 01/57057 (2001-08-01), None
patent: WO 01/60990 (2001-08-01), None
patent: WO 01/71045 (2001-09-01), None
patent: WO 01/72701 (2001-10-01), None
patent: WO 01/80903 (2001-11-01), None
patent: WO 01/85953 (2001-11-01), None
patent: WO 2007053447 (2007-05-01), None
Lewin. Genes IV. 1990. Oxford University Press, p. 810.
Abe et al., “Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and tumor cell growth,”J. Lipid Res.36(3):611-621 (1995).
Abe et al., “Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase,”Kidney Int.57(2):446-454 (2000).
Abe et al., “Use of Sulfobutyl Ether-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3-morpholinopropanol-Related Glucosylceramide Synthase Inhibitors,”.Anal. Biochem.287(2):344-347 (2000).
Ambati, “Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies,”Surv. Ophthalmol.48(3):257-293 (2003) (Abstract Only).
An et al., “Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids,”FEBS Letts.417(3):279-282 (1997).
An et al., “Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphotatidic Acid,”J. Biol. Chem.273(14):7906-7910 (1998).
An et al., “Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5,”J. Biol. Chem.275(1):288-296 (2000).
Ancellin et al., “Extracelluar export of sphingosine kinase-1 enzyme: Sphingosine 1 phosphate generation and the induction of angiogenic vascular maturation,”J. Biol. Chem.277(8):6667-6675 (2001).
Andrieu-Abadie et al., “L-camitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation,”FASEB J.13(12):1501-1510 (1999).
Arenz et al., “Synthese des ersten selektiven irreverilben Inhibitors der neutralen Sphingomyelinase,”Angew Chem.112:1498-1500 (2000) (GERMAN); “Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase,”Angew. Chem. Int. Ed.39(8):1440-1442 (2000) (English Equivalent).
Arenz et al., “Manumycin A and its Analogues Are Irreversible Inhibitors of Neutral Sphingomyelinase,”Chem. Biochem.2(2):141-143 (2001).
Arenz et al., “Synthesis and Biochemical Investigation of Scyphostatin Analogues as Inhibitors of Neutral Sphingomyelinase,”Bioorg. Medicinal Chem.9(11):2901-2904 (2001).
Arenz et al., “Synthesis of the First Selective Irreversible Inhibitor of Neutral Sphingomyelinase,”Eur. J. Org. Chem.2001(1):137-140 (2001).
Ariga et al., “Role of Sphingolipid-mediated cell death in neurodegenerative diseases,”J. Lip. Res.39(1):1-16 (1998).
Bajjalieh et al., “Ceramide Kinase,”Methods Enzymol.311:207-215 (1999).
Barbone et al., “Robotic Assay of Sphingomyelinase Activity for High Throughput Screening,”Meth. Enzymol.311:168-176 (1999).
Bawab et al., “Molecular Clonging and Characterization of a Human Mitochondrial Ceramidase,”J. Biol. Chem.275(28):21508-21513 (2000).
Bernardo et al., “Purification and Characterization of Magnesium-dependent Neutral Sphingomyelinase from Bovine Brain,”J. Biol. Chem.275(11):7641-7647 (2000).
Betto et al., “Sphingosylphosphocholine modulates the ryanodine receptor/calcium-release channel of cardiac sarcoplasmic reticulum memberances,”Biochem. J.322(1):327-333 (1997).
Bielawska et al., “(1S,2R)-D-erhthro-2-(N-My- ristoylamino) -1-phenyl-1-propanol as an Inhibitor of Ceramidase,”J. Biol. Chem.271(21):12646-12654 (1996).
Bielawska et al., “Ceramide Is Involved in Triggering of Cardiomyocyte Apoptosis Induced by Ischemia and Reperfusion,”Am. J. Pathol.151(5):1257-1263 (1997).
Boudker et al., “Detection and Characterization of Ceramide-1-phosphate Phosphatase Activity in Rat Liver Plasma Membrane,”J. Biol. Chem.268(29):22150-22155 (1993).
Brady et al., “The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease,”Proc. Natl. Acad. Sci. USA55(2):366-369 (1966).
Brindley et al., “Anal
Garland William A.
Hansen Genevieve
Jones Steven Tarran
Sabbadini Roger A.
Williams David Gareth
Acuity Law Group, P.C.
Chambers Daniel M.
Gussow Anne M.
Lpath, Inc.
LandOfFree
Humanized antibodies and compositions for binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies and compositions for binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies and compositions for binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297542